Radically different
Nature Biotechnology, Published online: 09 July 2026; doi:10.1038/s41587-026-03211-3
From virtual patients to simulated cells and organs-on-chips, digital twins are forecasting disease and guiding drug development. Scientists now must figure out how to define, validate and deploy these models.
Nature Biotechnology, Published online: 09 July 2026; doi:10.1038/s41587-026-03188-z
PALACE combines homology features and deep learning to improve phage assembly from metagenomics.
Nature Medicine, Published online: 09 July 2026; doi:10.1038/s41591-026-04512-5
The immune-privileged environment of the inner ear permits sequential bilateral gene therapy for one form of congenital deafness, which adds to growing evidence of the feasibility, safety and efficacy of this innovative curative treatment.
Nature Medicine, Published online: 09 July 2026; doi:10.1038/s41591-026-04490-8
The 2024 revision of the McDonald diagnostic criteria is an important step toward earlier and more inclusive diagnosis of multiple sclerosis. Realizing its full potential will require continued refinement of biomarkers, disease stratification and clinical trial approaches.
Nature Medicine, Published online: 09 July 2026; doi:10.1038/s41591-026-04484-6
Once confined to post-market surveillance, real-world evidence is now being used to emulate trials, guide approvals and even run studies in real time, forcing a rethink of what constitutes a clinical trial.
Nature Medicine, Published online: 09 July 2026; doi:10.1038/s41591-026-04538-9
In phase 1b/2 trial, the treatment of patients with metastatic KRASG12D-mutant pancreatic cancer, the intravenously delivered KRAS-G12D inhibitor HRS-4642 plus nab-paclitaxel and gemcitabine led to encouraging clinical response rates that support investigation in larger trials.
Nature Medicine, Published online: 09 July 2026; doi:10.1038/s41591-026-04495-3
This review outlines the state of the art of biological clocks and how they could help understand pathobiology, reduce the burden of disease and extend healthspan.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning, everyone. Now that we’ve all narrowly survived a workday without the World Cup, we can at last return to our new normalcy this afternoon for France 3-1 Morocco.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Northwest Biotherapeutics, a public biotech company developing a treatment for brain cancer, submitted a marketing application to U.K. regulators in late December 2023. The review was supposed to take 150 days, under an expedited regulatory pathway for drugs that address serious unmet medical needs.
As you’re reading this newsletter, two years, six months, and 18 days have elapsed without an approval decision. Why the extra-long delay? Regulators at the U.K’s Medicines and Healthcare products Regulatory Agency, or MHRA, won’t comment, telling anyone who inquires, including me, that it’s up to Northwest Bio to provide an update on its brain cancer treatment, called DCVax.
LONDON — In a blow to its cardiovascular aspirations, AstraZeneca said Thursday that its drug for a heart disease — one that has become an increasingly competitive target for biopharma companies — failed in a pivotal trial.
The drug, called Wainua, on which AstraZeneca is partnered with Ionis Pharmaceuticals, did not outperform placebo in reducing cardiovascular death and clinical events for patients with a condition known as ATTR-CM, or transthyretin-mediated amyloid cardiomyopathy.
AstraZeneca’s U.S. shares were down some 8% in premarket trading, while its London-listed shares were down 9% early Thursday. Ionis shares, meanwhile, were down 12% in premarket hours.